Article thumbnail

First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia

By Frank Peinemann, Ulrich Grouven, Nicolaus Kröger, Carmen Bartel, Max H. Pittler and Stefan Lange
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3081818
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution. Military Medicine.
  2. (1991). Acquired aplastic anaemia: still a serious disease.
  3. (2009). Acquired aplastic anemia in childhood.
  4. (1990). Acquired severe aplastic anaemia in adults–a single centre study with 13 years follow-up.
  5. (2009). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant.
  6. (2006). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe.
  7. (2007). Allogeneic stem cell transplantation for aplastic anemia.
  8. (2007). An update on the management of severe idiopathic aplastic anaemia in children.
  9. (1979). Antilymphocyte globulin treatment in severe aplastic anemia–comparison with bone marrow transplantation. Report of 60 cases.
  10. (2005). Aplastic anaemia.
  11. (2008). ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia– systematic review and meta-analysis.
  12. (2010). Bloodjournal of the American Society of Hematology, ASH Annual Meeting Abstracts: search terms=aplastic + anemia + transplantation. Washington: American Society of Hematology (ASH).
  13. (1983). Bone marrow graft versus ALG in patients with aplastic anaemia.
  14. (1988). Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party.
  15. (2010). Clinical Trials: search terms=aplastic + anemia + transplantation. Bethesda: National Institutes of Health (NIH).
  16. (2004). Commentary: Mendelian randomization–an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.
  17. (1984). Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia.
  18. (1997). Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.
  19. (2006). Current concepts in the pathophysiology and treatment of aplastic anemia.
  20. (2002). Direction and impact of language bias in meta-analyses of controlled trials: empirical study.
  21. (2004). Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.
  22. (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
  23. (2005). Glossary of Terms (Version 4.2.5). Oxford: The Cochrane Collaboration.
  24. (2009). Guidelines for the diagnosis and management of aplastic anaemia.
  25. (2000). Guidelines for treating of aplastic anemia. London: European Group for Blood and Marrow Transplantation (EBMT) Aplastic Anaemia Working Party (AAWP).
  26. (2000). Guidelines for Treatment of Aplastic Anemia. Consensus Document of a group of interntional experts.
  27. (1999). High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia–A possible role of high endogenous IL-2 in their suppression.
  28. (2002). How should meta-regression analyses be undertaken and interpreted?
  29. (1991). How to avoid bias when comparing bone marrow transplantation with chemotherapy.
  30. (2005). Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.
  31. (1989). Immunosuppressive therapy versus bone marrow transplantation for children with aplastic anemia.
  32. (1997). Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?
  33. (1999). Improved prognosis for acquired aplastic anaemia.
  34. (2000). Improved survival in severe acquired aplastic anemia of childhood.
  35. (1988). Late haematological complications in severe aplastic anaemia.
  36. (2000). Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
  37. (1995). Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.
  38. (2006). Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program.
  39. (2003). Measuring inconsistency in meta-analyses.
  40. (2007). MeSH Data Changes -
  41. (2006). MeSH Tree Number Changes -
  42. (1986). Meta-analysis in clinical trials.
  43. (1990). Mousavi A (2004) Bone marrow transplantation versus immunosuppressive therapy in severe aplastic anemia,
  44. (2010). Office of Rare Diseases Terms: Aplastic anemia. Bethesda: National Institutes of Health (NIH).
  45. (2003). Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial.
  46. (2007). Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).
  47. (2007). Practical methods for incorporating summary time-to-event data into meta-analysis.
  48. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
  49. (1997). Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team.
  50. (2000). Publication and related biases.
  51. (2005). Qualityadjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia.
  52. (1998). Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.
  53. (2006). Relative incidence of agranulocytosis and aplastic anemia.
  54. (2009). Section 13.5. Assessing risk of bias in non-randomized studies.
  55. (2009). Section 13.6.2.4 When pooling is judged not to be appropriate.
  56. (2009). Section 7.7.7 Data extraction for estimates of effects.
  57. (2009). Section 9.4.3 A generic inverse-variance approach to metaanalysis.
  58. (2009). Section 9.5.2 Identifying and measuring heterogeneity.
  59. (1989). Severe acquired aplastic anemia in children: 11-year experience with bone marrow transplantation and immunosuppressive therapy.
  60. (1980). Severe aplastic anemia: A prospective study on the value of different therapeutic approaches in 37 successive patients.
  61. (2007). The crux of the log rank test.
  62. (2006). The demise of the randomised controlled trial: bibliometric study of the German-language health care literature,
  63. (2010). The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews.
  64. (2003). The inclusion of reports of randomised trials published in languages other than English in systematic reviews.
  65. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
  66. (2003). The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea.
  67. Transplantation, deleted MN:
  68. (2000). Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–The European Group for Blood and Marrow Transplantation experience.
  69. (1977). Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions.
  70. (1984). Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody.
  71. (1981). Treatment of severe aplastic anaemia with antilymphocyte globulin or bonemarrow transplantation.
  72. (1994). Treatment of severe aplastic anemia: A longterm followup of 175 patients on antilymphocyte globulin or bone marrow transplantation.
  73. (1984). Treatment of severe aplastic anemia: a prospective study of antilymphocyte globulin versus bone marrow transplantation.
  74. (1989). Treatment of severe aplastic anemia: comparison of bone marrow transplantation to immunotherapy.
  75. (1986). Treatment of severe aplastic anemia.
  76. (2008). Treatment strategies for patients with severe aplastic anemia.
  77. (1990). Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party.